Wirth is one of several clients represented by the firm Parker Waichman LLP, which is currently pursuing legal action against manufacturers of popular GLP-1 medications. The litigation centers on claims that companies failed to provide adequate warnings to patients and physicians regarding non-arteritic anterior ischemic optic neuropathy, or NAION—a condition that can cause sudden, permanent vision loss without warning or pain.

Jason Goldstein, senior litigation counsel at Parker Waichman and a member of the federal litigation’s executive committee, argues that the legal focus is on the adequacy of risk disclosure. While researchers at Massachusetts Eye and Ear continue to study the potential links between semaglutide and optic nerve damage, drug manufacturers involved in the suits have denied the allegations, maintaining that the current evidence does not establish a causal connection between their products and the condition.